Table 5.
All Adverse Events.
| Adverse Events | CCP-ACI Group, n (%) | MFx Group, n (%) |
|---|---|---|
| Eye disorders | ||
| Eye pain | 0 (0.0) | 1 (7.1) |
| Gastrointestinal disorders | ||
| Constipation | 4 (20.0) | 0 (0) |
| Dental cyst | 1 (5.0) | 0 (0) |
| Nausea | 3 (15.0) | 2 (14.3) |
| Esophagitis | 0 (0) | 1 (7.1) |
| Vomiting | 1 (5.0) | 2 (14.3) |
| Infections and infestations | ||
| Bacterial vaginosis | 0 (0) | 1 (7.1) |
| Chronic sinusitis | 1 (5.0) | 0 (0.0) |
| Rhinitis | 0 (0.0) | 1 (7.1) |
| Upper respiratory tract infection | 1 (5.0) | 0 (0.0) |
| Viral upper respiratory tract infection | 0 (0.0) | 2 (14.3) |
| Injury, poisoning and procedural complications | ||
| Chemical eye injury | 1 (5.0) | 0 (0) |
| Postprocedural hematoma | 1 (5.0) | 0 (0) |
| Postoperative adhesion | 1 (5.0) | 0 (0) |
| Metabolism and nutrition disorders | ||
| Dyslipidemia | 0 (0) | 1 (7.1) |
| Musculoskeletal and connective tissue disorders | ||
| Back pain | 1 (5.0) | 0 (0) |
| Musculoskeletal pain | 1 (5.0) | 0 (0) |
| Neck pain | 1 (5.0) | 0 (0) |
| Temporomandibular joint syndrome | 0 (0) | 1 (7.1) |
| Nervous system disorders | ||
| Dizziness | 1 (5.0) | 1 (7.1) |
| Headache | 1 (5.0) | 0 (0.0) |
| Renal and urinary disorders | ||
| Calculus urinary | 0 (0) | 1 (7.1) |
| Skin and subcutaneous tissue disorders | ||
| Dermatitis contact | 1 (5.0) | 0 (0) |
| Total cases, n (%) | 20 (100) | 14 (100) |
CCP-ACI, costal chondrocyte–derived pellet-type autologous chondrocyte implantation; MFx, microfracture.